RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases

Area of Science:

• Cardiovascular Disease Research
• Endocrinology
• Molecular Biology

Background:

• Receptor for advanced glycation end-products (RAGE) is implicated in diabetic microvascular and macrovascular complications.
• RAGE plays a role in atherogenesis, angiogenesis, vascular injury, and inflammation, impacting cardiovascular disease (CVD) in both diabetic and nondiabetic individuals.
• Truncated forms of RAGE, particularly soluble RAGE (sRAGE), have emerged as significant players.

Purpose of the Study:

• To review the pathophysiological roles of RAGE and sRAGE in cardiovascular disease.
• To discuss the potential of RAGE and sRAGE as therapeutic targets and biomarkers for CVD.

Main Methods:

• Literature review summarizing recent findings on RAGE and sRAGE in CVD.
• Discussion of ELISA systems for measuring plasma esRAGE and total sRAGE.
• Analysis of in vitro and in vivo studies on sRAGE ligand binding and signaling antagonism.

Main Results:

• Soluble RAGE, including endogenous secretory RAGE (esRAGE) and shed sRAGE, antagonizes RAGE signaling by binding ligands like AGEs.
• Clinical studies are beginning to unveil the pathophysiological roles of sRAGE.
• RAGE and sRAGE are involved in key processes underlying CVD pathogenesis.

Conclusions:

• RAGE and its soluble forms are critical in the development and progression of cardiovascular disease.
• Soluble RAGE presents potential as a therapeutic target and a clinical biomarker for cardiovascular conditions.
• Further research into RAGE and sRAGE pathways is warranted for effective CVD management.